Is Fractional exhaled nitric oxide (FeNO) test reliable in the differentiation of chronic obstructive pulmonary disease (COPD) and ACOS (asthma-COPD overlap syndrome)? Source: International Congress 2017 – Lung function testing in different patient categories Year: 2017
Differential assessment of airway inflammation in chronic obstructive pulmonary disease (COPD) by measurements of exhaled nitric oxide (NO) derived from peripheral vs. central airways Source: Eur Respir J 2003; 22: Suppl. 45, 279s Year: 2003
Using fractional exhaled nitric oxide level to differentiate asthma–COPD overlap syndrome from COPD Source: International Congress 2018 – Airway disease: recent discoveries Year: 2018
Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function Source: Eur Respir J 2001; 17: 934-938 Year: 2001
Fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019
Fractional exhaled nitric oxide in chronic obstructive pulmonary disease Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH) Source: Eur Respir J 2001; 18: Suppl. 33, 83s Year: 2001
Exhaled nitric oxide in respiratory diseases other than asthma Source: Eur Respir Monogr 2010; 49: 45-55 Year: 2010
Use of different exhaled nitric oxide multiple flow rate models in COPD Source: Eur Respir J 2007; 29: 651-659 Year: 2007
Alveolar but not airway fractional exhaled nitric oxide concentration (FENO) is decreased in obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2003; 22: Suppl. 45, 467s Year: 2003
Relationship between baseline fraction of exhaled nitric oxide (FeNO) and response to anti-IL-5/5R therapies in severe eosinophilic asthma (SEA) Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Concentration of exhaled nitric oxide (FENO ) in patients with obstructive sleep apnea Source: Eur Respir J 2004; 24: Suppl. 48, 118s Year: 2004
Two sites of airway obstruction identified by post-bronchodilation change of exhaled nitric oxide in COPD patients Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016
The influence of asthma and COPD exacerbation on exhaled mitric oxide (FENO ) Source: Eur Respir J 2004; 24: Suppl. 48, 409s Year: 2004
Exercise training and exhaled nitric oxide (eNO) in COPD patients of different severity Source: Eur Respir J 2001; 18: Suppl. 33, 222s Year: 2001
Exhaled nitric oxide and hydrogen peroxide in patients with asthma and chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 617s Year: 2007
Stability of exhaled nitric oxide (FE NO) in patients with severe, steroid-dependent asthma Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008
Exhaled nitric oxide in obstructive sleep apnea (OSA) patients: short and long term response to automatic positive airway pressure (APAP) therapy Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Is exhaled nitric oxide (eNO) an indipendent outcome measure in chronic stable asthma? Source: Eur Respir J 2002; 20: Suppl. 38, 196s Year: 2002
Reduced pulmonary capillary volume (Vc) is responsable for the increased alveolar exhaled nitric oxide (CA NO) in patients with progressive systemic sclerosis (PSS) and pulmonary hypertension (PH) Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005